You just read:

U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer

News provided by

Astellas Pharma Inc.

11 Sep, 2014, 20:34 BST